Indications for: NAMENDA
Moderate-to-severe dementia of the Alzheimer's type.
Initially 5mg once daily; titrate at intervals of at least 1 week to 5mg twice daily, then to 5mg and 10mg as separate doses, then to 10mg twice daily (prescribe Titration Pak for 1st 4 weeks). Severe renal impairment (CrCl 5–29mL/min): titrate to max 5mg twice daily.
Severe hepatic impairment. Alkalinized urine (eg, renal tubular acidosis, severe UTI) increases memantine serum levels. Seizure disorder. Pregnancy. Nursing mothers.
NMDA receptor antagonist.
Caution with other NMDA antagonists (eg, amantadine, ketamine, dextromethorphan). May affect or be affected by renally-excreted drugs (eg, triamterene, HCTZ, metformin, cimetidine, nicotine, ranitidine, quinidine). Plasma levels may be increased by urinary alkalinizers.
Headache, dizziness, confusion, diarrhea, constipation, hypertension, pain, somnolence, hallucination, urinary disorders, dyspnea.
Renal. Half-life: ~60–80 hours.
Generic Drug Availability:
Tabs—60; Titration Pak (28 x 5mg + 21 x 10mg)—1; Oral soln—contact supplier; XR caps 7mg, 21mg—30; 14mg, 28mg—30, 90; XR Titration Pak (7 x 7mg + 7 x 14mg + 7 x 21mg + 7 x 28mg)—1